SPONSOR
Chiesi Farmaceutici S.p.A.
Total Trials
2
Recruiting
2
Phases
Phase 2, Phase 1, Phase 2
NCT07301736 Phase 2
Recruiting
Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
Asthma
NCT06166056 Phase 1, Phase 2
Recruiting
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis
Bronchiectasis